Difgen Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DIFGEN PHARMS
DIFGEN PHARMS has seven approved drugs.
Summary for Difgen Pharms
| US Patents: | 0 |
| Tradenames: | 14 |
| Ingredients: | 7 |
| NDAs: | 7 |
Drugs and US Patents for Difgen Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Difgen Pharms | MESALAMINE | mesalamine | CAPSULE, EXTENDED RELEASE;ORAL | 219997-002 | Mar 10, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Difgen Pharms | FENTANYL-50 | fentanyl | FILM, EXTENDED RELEASE;TRANSDERMAL | 077449-002 | Oct 20, 2008 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Difgen Pharms | FENTANYL-87 | fentanyl | FILM, EXTENDED RELEASE;TRANSDERMAL | 077449-008 | Dec 6, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
